[
  {
    "request": {
      "base_url": "https://openrouter.ai/api/v1",
      "model": "openai/gpt-5-mini",
      "messages": [
        {
          "role": "user",
          "content": "A patient who has recently gone into remission from lymphoma was previously on high doses of opioids and is now facing challenges in weaning off them. The patient wonders if buprenorphine-naloxone (Suboxone) could be part of their tapering plan. \n\nConsidering the patient's situation, review the following options then select the best statement(s):\nI. Maintain the patient on their current opioid regimen, focusing on gradually reducing dosage over time without introducing new medications to avoid potential side effects.\nII. Transition the patient to methadone, which is approved for both pain and opioid use disorder management; it offers a highly regulated dosage and reduces potential withdrawal complications.\nIII. Initiate a rapid opioid tapering strategy, augmented with non-opioid pain management interventions, emphasizing complete opioid cessation as the primary goal.\nIV. Arrange a multidisciplinary consultation, involving pain management and psychiatry, to assess the psychological and physical aspects and develop an integrated tapering approach.\nV. Prescribe buprenorphine-naloxone, as it is effective for managing opioid use disorder symptoms, including withdrawal and cravings, even though its primary indication is not for chronic pain.\n\nAnswer Choices:\nA. I, II\nB. I, III\nC. I\nD. II, V\nE. I, II, IV\nF. II, III\nG. IV, V\nH. II, IV, V\nI. V\nJ. II, III, IV\nK. I, II, III\nL. III, V\nM. I, IV\nN. II\nO. II, IV\nP. III, IV\nQ. IV\nR. III\nS. I, V\nT. I, III, IV\nU. I, IV, V"
        }
      ],
      "reasoning_effort": "medium",
      "response_format": {
        "type": "json_schema",
        "json_schema": {
          "name": "answer",
          "strict": true,
          "schema": {
            "type": "object",
            "properties": {
              "answer": {
                "type": "string"
              },
              "answer_letter": {
                "type": "string",
                "enum": [
                  "A",
                  "B",
                  "C",
                  "D",
                  "E",
                  "F",
                  "G",
                  "H",
                  "I",
                  "J",
                  "K",
                  "L",
                  "M",
                  "N",
                  "O",
                  "P",
                  "Q",
                  "R",
                  "S",
                  "T",
                  "U"
                ]
              }
            },
            "required": [
              "answer",
              "answer_letter"
            ],
            "additionalProperties": false
          }
        }
      },
      "usage": {
        "include": true
      }
    },
    "response": {
      "id": "gen-1762208073-EcdHAZ3ISOmBz9MbeZyW",
      "choices": [
        {
          "finish_reason": "stop",
          "index": 0,
          "logprobs": null,
          "message": {
            "content": "{\"answer\":\"Best choices: IV and V. Arrange multidisciplinary consultation (pain management, psychiatry) to create an individualized, supported taper, and consider buprenorphine\u2013naloxone as a valid option to manage withdrawal and cravings or to facilitate transition from high\u2011dose opioids (noting it is primarily indicated for OUD and must be started carefully to avoid precipitated withdrawal). Methadone and rapid tapering or rigid avoidance of other medications are not generally the preferred first choices in this situation.\",\"answer_letter\":\"G\"}",
            "refusal": null,
            "role": "assistant",
            "annotations": null,
            "audio": null,
            "function_call": null,
            "tool_calls": null,
            "reasoning": "**Evaluating tapering methods**\n\nI'm looking into tapering strategies and noting that rapid tapering carries withdrawal risks, so a gradual, individualized approach is best. I want to avoid introducing new medications during this process, but maintaining the current opioid regimen while planning a slow taper seems reasonable. There\u2019s a concern that recommending treatment options may be overly restrictive. Transitioning to methadone could be a regulated choice for pain and opioid use disorder, but it requires careful management and monitoring.**Choosing treatment options**\n\nI\u2019m analyzing buprenorphine-naloxone's role in managing opioid use disorder (OUD), noting it's effective for withdrawal and cravings even if it\u2019s not mainly for chronic pain. It\u2019s also reasonable to consider tapering from high-dose opioids to buprenorphine, but I need to manage the risk of withdrawal. Statements IV and V seem to fit best, suggesting a multidisciplinary consultation and prescribing buprenorphine-naloxone. I\u2019ll opt for G. Time to prepare a JSON response with my answer!**Formatting the response**\n\nI need to ensure my output includes the required fields: \"answer\" and \"answer_letter\". I\u2019ll keep it brief while explaining why I didn't select options I, II, and III. It\u2019s important to confirm that buprenorphine could indeed be part of the treatment plan, but I must explain succinctly. By not choosing those options, I can emphasize the rationale behind selecting the appropriate course of action based on the patient\u2019s needs. Time to craft that concise explanation!",
            "reasoning_details": [
              {
                "type": "reasoning.summary",
                "summary": "**Evaluating tapering methods**\n\nI'm looking into tapering strategies and noting that rapid tapering carries withdrawal risks, so a gradual, individualized approach is best. I want to avoid introducing new medications during this process, but maintaining the current opioid regimen while planning a slow taper seems reasonable. There\u2019s a concern that recommending treatment options may be overly restrictive. Transitioning to methadone could be a regulated choice for pain and opioid use disorder, but it requires careful management and monitoring.**Choosing treatment options**\n\nI\u2019m analyzing buprenorphine-naloxone's role in managing opioid use disorder (OUD), noting it's effective for withdrawal and cravings even if it\u2019s not mainly for chronic pain. It\u2019s also reasonable to consider tapering from high-dose opioids to buprenorphine, but I need to manage the risk of withdrawal. Statements IV and V seem to fit best, suggesting a multidisciplinary consultation and prescribing buprenorphine-naloxone. I\u2019ll opt for G. Time to prepare a JSON response with my answer!**Formatting the response**\n\nI need to ensure my output includes the required fields: \"answer\" and \"answer_letter\". I\u2019ll keep it brief while explaining why I didn't select options I, II, and III. It\u2019s important to confirm that buprenorphine could indeed be part of the treatment plan, but I must explain succinctly. By not choosing those options, I can emphasize the rationale behind selecting the appropriate course of action based on the patient\u2019s needs. Time to craft that concise explanation!",
                "format": "openai-responses-v1",
                "index": 0
              },
              {
                "type": "reasoning.encrypted",
                "data": "gAAAAABpCSlW-w7EIsVthQs_xlyrbEN6hXX-zD_Z73yr9fX2vgNaL8haCenD2Qwg0Tj8HfT9i4hadbUZx3CJo_lXQrJ4tFPJ0SirntgOyOphv42J0p9dQPl5QcNqkmrEXWsYHuK00FyR2CUMQy_kIuxHUgmLNqJVbRY77a3o2UZ76Gn2UxnF-L7T2ohqO9b-RNCaQqu9zGSVLcK62nPm7JDMN9GwT2Z6yE2pvWfA4QpVZlW7y1yq9VUcUOlKKh6NdGCk5i8vD0X5VF4SVxTyPXCrH3PgcCMv8T8F55gTqWcz5DK14prcJtNjQE7OnoHS4_ifWLrhLblWQCWwI8Ktwnmdwj-zVPYh7c7luLX0IjYyiWQp4nApJ_Ew7P0G6FwPWg8OesJ9yg5eB0AAhZWAkP3q4bW4HMo-OVKjiQg87EIyk9_28_B8rWIyfElPV_5CEXHu4SSq1ZJIkmdkBFR4XkJxzamrpr5xHOOaC2RCnqvuAqWgCqMYaDjhcTbgAeSUBPrs0_-gng2QnGFUO_q2DT97eMvxb-KE7afnW6sMFbTHpVgyii5iGFjW-3eYtQIcBS3Ieyn6OMmLQzDKWjQC8oRy0Ba3acn7Z1xmOmqVp7SUVQqslPWZwMaaDd0gV9WUmW5U3OscIj5fowBSsXvN9spK_Vgf385E-WoVe-n3t2M_lOiolVJwcP8Hl6z6MLtDXPiLxx5_AgqUqoIcWxdtSYPwIs8gAKoTau3cQLBjQ3VlOJf5HbHwiy9_EHNv4ced13mT2FDJQ8uKW3kV1c_zkDlnC_mhUY0N3Xa0fEb-n3k0YqC_pvTALTYbLfQrP1GAs6ofMn8LY3uvAaf-asIKp2arGVKg8Qj2VJjxvlZyciapxSkIf3yIMfAvGA11uwpB8HBNfYLHiPGnwe90MEn-uqR63k2K44cn0YKXPUYFMTFDjUO99PBLQJd4FCp56ld19lkmUXFufPf0FkKTBavhIQvIMjQZFjnzMg9MqXH46Pta8Mm22EdXCYD8iaJB3ciD3Mz0tH70xFfjzHtcxil5ODfO8ttfPwJeGgKiP3w-H8Lt0F6ErDQl69Ek3EeiBGzYZVfHjVnhYYyJ6nR6ugnr10UNzb5GD2RHneaiYUxJf750DBYJ4qjY_t-Nv4L0UcS07oeC7_csKRlFSeUZBy9uzo_2qNbxlVmJxCXKVFDRXQvIg2mGK5FyXAhsaekcVdGdxLh8uggZd1Zpn7y8sY4lte5lukMdVJwlAShdFAN548ROL17BGUzfiMMFf0qqqa0WkslGptNOa1zR20OYLlvaiOmjLygb0lnJxQysimPPs_pE7QH2UVTR4n3VydGLl8dD2SyeR2xkz0yo-3NXIaUmnhKULRkZo46JXpoEsW-g6G187VhUvqVm2_mca-kLWK1gyM1orLDPPgkiVytkviTxKQtd5j-aygDURLuT7dC804HNKPvQM5u86wwml0yBwPnkxinNrheMzmqSrqEes1Ur7hzgBhvhqSlA2Zz8RmkSDvdoIfrZbsVPA6xjFf-nmwFL0xAMt7etlNAHodltTs_RSadkHgx2n-4MK29AtJbk5Pqv5Pl3SeRmqhW6MfU62URAa9lhH70wNaw88lxoRNCjkt07WnmLdglcLftsXJcGJ9ft5DootO5BQXArJPVfwojo5rl5xzvf2uFI13_esFYaFHOQ5zHbjXRgpWNFchE8E0mWFToppGKYSBD01H4kROD6lCpSLVOf76TGJHdSE0R0Fd-XN2MmvvTBxB0Lq1CUxZzr7Izy-OdUl5RpRsYcq4Zj4gbKKhk-Ek1OhAFp_oKdabqn42YwJlY8K7wd6YSM9RJWNtiV6Ou52bYaZItLRfesF8cSJHH2N8oQmckNsJhhK07kwf8Sc3CMZm7avYZ5f3S2tbHKe1pILhO6r03xwR9izDyIZ5A6Ws-lndTO-6kfxyhUqj4oRKIdH69YpzReMKu68NBIzVcxyhmVPmSvmYvQRL8kuVG6U4B79Jrmc7TFQ-yoi34jwJelilekxPkxmD4FW7fS-2o-XPTJ-4VXJiHO6c8S6fbv_ph4CzVYCmfuTboHsfXGAGmPSUvPJjVFT5LmlH102TBB5S-8lb0Di4quSiyu98MBtP52BHn_bCBmDMGvgBRsvls9TBksv9cQ77IpUbYVFMosGrbKzauIAk53EfrLrMBhrcf6fmk1QVIQoVLajkdBhsCbQqPZnoNUz-QVSdVaP2K39ffq1L9RjNtyhaH5551L7P-Y2GU6SimaLWt3qLQQXc-puIHrFiQnkajWoQ5xkEy-xKtgv6ETLLudyi1ATDbWlfpOwtG5rttHGP3W62cMthIMdMkjzO3xDxGrLeyxKd1sd5StmxMVHr9CtA7d-7jFb56ZIExgGle488_6mtFZQwHqelRigS4EnclzO3OKrJrh5ch6MD__BOQQlQ-MHJ4t2c9P8XD1ef5fg3CtjJ2SkFqngtmIfBoOVzrtPI1nelDrAf3q3Ikx_3Ht53TSfF1YjPYPs4cRWZNUW1hkk4HYyML8bH09oJe27kal4WWCD3VH4hHN1eHhCdGkTYCo7nj6nKrtZEak6DP2Y_aOgEimjwHTYNbIX0S1lK1vYTvOT7gWbMLDLYLo6Hbqie8Ir58GGpUeW2OHQrsN3faTQz8a7SHIbk6oclddGBra-RpT0k79as1YYu3Wnp0Nmk364C8tyh5qhlvfCau1YtBMgS-ZrAF4miagWUO7icTOWrTuFMGzXlyp0jsG9wty84U_Gjl3LuWZVbQSMervD6qrYup0o7V2YgO44qfDXm4jeYBVjUOQRLo5ggWYWYVgXDc_qx4A4uht7lOmoALStEXH5OssuOGwdudCdWPTbCnOv_l_Nz90pa9IZuQ7ofdWjVNlWUecYKArUjJfMQ34Dz31CXm7tH5v0Ql3YZ2hfWAS6QG7MlYUG-UiI_feLLLXY0r3t9dQUEQ8gAlbvgKr2LrzJ4GWXuUMJAIDZgm4mwZCaYu8Jksy5ko9CtQ-h3ZCaa1iyZFVsrkh6nTXR0-BT8BwnPpRa4ohuE3oVlYbiR96SV3xjhc03TetktbrcsiLZQrO8K8VT8trJy1G6OxOtMe4CeryBkN7f6lni83G2oL-upUCH7UTSvACDWyygwfFi4g1KklZi8CV-sPyA0GVPh3q7AfmCm29WTrv8KPFoJOYeGvXqDjc0zaX6Ujs62FNbJFZSUm7g8j5z4m6v0RCjvi0THBy42O-O3AnK_BRu8vGvTektq101jzTzgc9hklVgMS0pOHsPGfi_GzSCi_ysb38WmgM0i3hOxzKtWgSSmok4OxrkSK3vxr5cAAEN0o4k6gAmn3sNLe_5Tmq1oJjNDkAgSDO-UZSy3aTXDqqOj4aRVi4UES9UBaMWw73iGWroPD11qdaa4hUCq-okm4z_2lMbJZhfk4zGyMYbrgHI6X9ieMOdGOOc4FnIyuy1Gh-8TCiz8LnBqj_OdDAoB1TvrGkwwVknZprZADJ5jMFDCvct55gZaddsSwA-QTFJ8iVes5JFCOTS-OcaWzt8wHheXyYa5qzn0tkN68FR84G_R5oybzLtSgql4TsxSrhe3Hyv16-CtywZhMvgNYdsBlxxMr530LV3mjQxX96qJ_RiXh9t3z0qjjkYAJ4kliFPVNfc1E1Tv9EIyX9sxNcNtSKtdz7-MF-JWycEtNm5Gd1bjDQJ1F_O9BH9gdwBYqAKR8M5HZhWfx4X1SqXfRMpmoc9UtTOiz1ZqOBSawNZJXXCyiakneSk-B-CEQhU5eyZvNhl36ELa0eWN_kf2zOf8RQwRRVHRctyZluznoj1yIaWt_kxMkFEv_4iH88sJ9Uwic5sluzDHRYOqNYziiXJeaSZ-tYSY6jG8vn7iOWDzMIadZqgXRaACQEODQkJSHerHh2xOqDYQbkPf8M5FOOZP7uxhkeCqzqXM-kaBPzFPAoaSWosUbENDRk_zK5vzdXDtXrOw1mrXbwySg84POPHvv0GZxH39kAvaxBdN-M2d0MhMhNbYJaLEyyWp6B8tcf3OfuHlkbwZEFgjbBu5D_HwCwJn2iPrwZ9EG6ulcPr2TmgIdDDwq_vjomxcUaoUKXrB2wyuFjPV4POUFYn3x8nH_Zj2FMY7a3KzaXtNVfwCaSYdpMBYAWwAIx77-WHyYQNAvYoiEZbXnlBRgA5qOjMWYRnpbICWfB9n3gItlWLrswOStBSkugcX18zvbYjijyx5QwPidGxzKflvztPXJg5DANnjeAJ1qsFNyrZ-zD2x8_-4GqQPaoc_oQ-raVIkOczcD0-mh0fGDJSK8z6aW2FRwsBFYKEqFj4F30_tmSONpbg5tzFPhU2jnv9T8c6wfuR_b0MEhd6oOPNw2-rz9ujZxJ0Aqp89yzc7W5Yh9374iyX9hdXlyub381ZmXva573q9O75hnUW1gf9r_Drr4pQw729A4EFMSF9rut6SB2BAiHcssAlTWwF1_m1nwE7ZlmQTmdEIFbj4V18yQS6XeylcYT81x4DFJ2Z1rWokKufAK8SJ39-ZrQ4vlLVbhIFNHCk_uPSfcZ_K1qszS7C2HSP7u1aBaNKZXAdvhqTyS7TsDlN90_jZDV1BL1bE5QUflM2361-l6OZn60bfJ1_DVxdt38Gj5qisXMC9z7hKa0D81OlSt3Qu5TRaH7DlsbQVWWrfWMH1s8pcGYngIONj3Z6djoD2yiN2a_NzTMtscuRxsbIJuPzhiX9XZqaQtSiNzDuSce9FazQRbUo-d_TCiMscbtTNTTZ2MyQXcKObo1PyYN65ndovsczebd5oitXMDss5O2qsTh47u_L3lz_p77V8GxE468VuQYjXi1rm0_K5vvzEOlnxe3nTskd6B-ptv5eww8vHndPn5tFdoOeh49ABq4HV7BVvLcSraiIoJrUrz6Lo0IFr9dt3BemwmR1LNbFFDYCWVCxPUB9jUYQfErLbOWHEvaWVwsd6TTsMRqgxOPe7I2m1yII18slthCFzgCFgMRbsbR3TptGxGegCxkyxRmkNPMtPvbsmPArUQlNx546VbJLFoa6KBShFRBwoaUwT-F4GBvIXNn_F4u0Fsmfzhq1ahvhTuWLZn_U4y3zjkMtexg-aVz5gZTEjF6_6cJpPRUS4Fvs5FdkFOz_3_vk1J72R0B4FZ9fKdOoEp8GWFKLBhQQouQ64Fyn2plnaLuTwD5tgB5Ek12kEYezIkxDwOHJHOHh9gmimmq0A==",
                "id": "rs_0311b68a3d7a62d9016909294a83e081979d87af3b16e39afd",
                "format": "openai-responses-v1",
                "index": 0
              }
            ]
          },
          "native_finish_reason": "completed"
        }
      ],
      "created": 1762208073,
      "model": "openai/gpt-5-mini",
      "object": "chat.completion",
      "service_tier": null,
      "system_fingerprint": null,
      "usage": {
        "completion_tokens": 692,
        "prompt_tokens": 443,
        "total_tokens": 1135,
        "completion_tokens_details": {
          "accepted_prediction_tokens": null,
          "audio_tokens": null,
          "reasoning_tokens": 576,
          "rejected_prediction_tokens": null,
          "image_tokens": 0
        },
        "prompt_tokens_details": {
          "audio_tokens": 0,
          "cached_tokens": 0
        },
        "cost": 0.00149475,
        "is_byok": false,
        "cost_details": {
          "upstream_inference_cost": null,
          "upstream_inference_prompt_cost": 0.00011075,
          "upstream_inference_completions_cost": 0.001384
        }
      },
      "provider": "OpenAI"
    }
  },
  {
    "request": {
      "base_url": "https://openrouter.ai/api/v1",
      "model": "openai/gpt-5-mini",
      "messages": [
        {
          "role": "user",
          "content": "A patient who has recently gone into remission from lymphoma was previously on high doses of opioids and is now facing challenges in weaning off them. The patient wonders if buprenorphine-naloxone (Suboxone) could be part of their tapering plan. \n\nConsidering the patient's situation, review the following options then select the best statement(s):\nI. Maintain the patient on their current opioid regimen, focusing on gradually reducing dosage over time without introducing new medications to avoid potential side effects.\nII. Transition the patient to methadone, which is approved for both pain and opioid use disorder management; it offers a highly regulated dosage and reduces potential withdrawal complications.\nIII. Initiate a rapid opioid tapering strategy, augmented with non-opioid pain management interventions, emphasizing complete opioid cessation as the primary goal.\nIV. Arrange a multidisciplinary consultation, involving pain management and psychiatry, to assess the psychological and physical aspects and develop an integrated tapering approach.\nV. Prescribe buprenorphine-naloxone, as it is effective for managing opioid use disorder symptoms, including withdrawal and cravings, even though its primary indication is not for chronic pain.\n\nAnswer Choices:\nA. I, II\nB. I, III\nC. I\nD. II, V\nE. I, II, IV\nF. II, III\nG. IV, V\nH. II, IV, V\nI. V\nJ. II, III, IV\nK. I, II, III\nL. III, V\nM. I, IV\nN. II\nO. II, IV\nP. III, IV\nQ. IV\nR. III\nS. I, V\nT. I, III, IV\nU. I, IV, V"
        }
      ],
      "reasoning_effort": "medium",
      "response_format": {
        "type": "json_schema",
        "json_schema": {
          "name": "answer",
          "strict": true,
          "schema": {
            "type": "object",
            "properties": {
              "answer": {
                "type": "string"
              },
              "answer_letter": {
                "type": "string",
                "enum": [
                  "A",
                  "B",
                  "C",
                  "D",
                  "E",
                  "F",
                  "G",
                  "H",
                  "I",
                  "J",
                  "K",
                  "L",
                  "M",
                  "N",
                  "O",
                  "P",
                  "Q",
                  "R",
                  "S",
                  "T",
                  "U"
                ]
              }
            },
            "required": [
              "answer",
              "answer_letter"
            ],
            "additionalProperties": false
          }
        }
      },
      "usage": {
        "include": true
      }
    },
    "response": {
      "id": "gen-1762208073-94335Mq7qRe6riPXWiQQ",
      "choices": [
        {
          "finish_reason": "stop",
          "index": 0,
          "logprobs": null,
          "message": {
            "content": "{\"answer\":\"G\\nArrange multidisciplinary input (pain, psychiatry/addiction) and consider buprenorphine\u2013naloxone for opioid withdrawal/craving management. Buprenorphine\u2013naloxone (Suboxone) is effective for treating opioid use disorder and can be part of a transition/taper plan, but requires proper induction (to avoid precipitated withdrawal) and coordination of care. Methadone is an option in some cases but requires specialized programs; rapid tapers or simply continuing high doses without broader assessment are not recommended.\",\"answer_letter\":\"G\"}",
            "refusal": null,
            "role": "assistant",
            "annotations": null,
            "audio": null,
            "function_call": null,
            "tool_calls": null,
            "reasoning": "**Evaluating treatment options**\n\nI need to choose the best statement regarding buprenorphine-naloxone for a patient recently in remission from lymphoma who previously used high doses of opioids and is now facing challenges in weaning off. \n\nThe first option suggests maintaining the current opioid regimen while tapering it down gradually. While tapering is often recommended, introducing new medications might also be beneficial. \n\nThe second option suggests transitioning to methadone, which is indeed approved for pain management and can help reduce withdrawal complications. This looks like a strong option!**Assessing treatment statements**\n\nI\u2019m evaluating statements about buprenorphine-naloxone for a patient managing opioid weaning. \n\nStatement II mentions methadone, which has risks and doesn\u2019t always suit typical chronic pain patients. While it\u2019s approved and can reduce withdrawal complications, it may not be the best first line for everyone. \n\nStatement III advocates rapid opioid tapering, which isn't recommended due to potential harms, making it false.\n\nHowever, statement IV suggests involving a multidisciplinary team for a supportive tapering plan, which is definitely a good idea! \n\nLastly, statement V supports using buprenorphine-naloxone for OUD symptoms, although it\u2019s not primarily for chronic pain. This aligns well with current treatment practices!**Evaluating treatment combinations**\n\nBuprenorphine-naloxone is primarily used for opioid use disorder (OUD) and works well for managing withdrawal and cravings. It's also being used to address pain alongside OUD. The statement that its primary indication isn\u2019t for chronic pain is true, especially since formulations like Suboxone focus on OUD.\n\nSo, statements IV and V are the best choices! As for statement II, while methadone might be considered, it requires specialized programs and isn\u2019t necessarily optimal here.\n\nConsidering the patient\u2019s needs, I\u2019d stick with statements IV and V, confirming that option G is likely the best overall choice!**Crafting a response**\n\nI'm concluding that while methadone can be an option, it has its risks and isn't necessarily the best choice. So, I\u2019ll go with option G, which includes statements IV and V.\n\nNow, I need to format my answer correctly. It should highlight that arranging a multidisciplinary consultation and considering buprenorphine-naloxone is reasonable since it's effective for OUD and can assist in tapering. \n\nI\u2019ll also note that starting buprenorphine-naloxone requires careful timing to avoid precipitated withdrawal if still using full agonists. Methadone might be an option, but it needs a specialist, making it not the first-line choice. I\u2019ll ensure to keep everything concise and present my answer clearly!",
            "reasoning_details": [
              {
                "type": "reasoning.summary",
                "summary": "**Evaluating treatment options**\n\nI need to choose the best statement regarding buprenorphine-naloxone for a patient recently in remission from lymphoma who previously used high doses of opioids and is now facing challenges in weaning off. \n\nThe first option suggests maintaining the current opioid regimen while tapering it down gradually. While tapering is often recommended, introducing new medications might also be beneficial. \n\nThe second option suggests transitioning to methadone, which is indeed approved for pain management and can help reduce withdrawal complications. This looks like a strong option!**Assessing treatment statements**\n\nI\u2019m evaluating statements about buprenorphine-naloxone for a patient managing opioid weaning. \n\nStatement II mentions methadone, which has risks and doesn\u2019t always suit typical chronic pain patients. While it\u2019s approved and can reduce withdrawal complications, it may not be the best first line for everyone. \n\nStatement III advocates rapid opioid tapering, which isn't recommended due to potential harms, making it false.\n\nHowever, statement IV suggests involving a multidisciplinary team for a supportive tapering plan, which is definitely a good idea! \n\nLastly, statement V supports using buprenorphine-naloxone for OUD symptoms, although it\u2019s not primarily for chronic pain. This aligns well with current treatment practices!**Evaluating treatment combinations**\n\nBuprenorphine-naloxone is primarily used for opioid use disorder (OUD) and works well for managing withdrawal and cravings. It's also being used to address pain alongside OUD. The statement that its primary indication isn\u2019t for chronic pain is true, especially since formulations like Suboxone focus on OUD.\n\nSo, statements IV and V are the best choices! As for statement II, while methadone might be considered, it requires specialized programs and isn\u2019t necessarily optimal here.\n\nConsidering the patient\u2019s needs, I\u2019d stick with statements IV and V, confirming that option G is likely the best overall choice!**Crafting a response**\n\nI'm concluding that while methadone can be an option, it has its risks and isn't necessarily the best choice. So, I\u2019ll go with option G, which includes statements IV and V.\n\nNow, I need to format my answer correctly. It should highlight that arranging a multidisciplinary consultation and considering buprenorphine-naloxone is reasonable since it's effective for OUD and can assist in tapering. \n\nI\u2019ll also note that starting buprenorphine-naloxone requires careful timing to avoid precipitated withdrawal if still using full agonists. Methadone might be an option, but it needs a specialist, making it not the first-line choice. I\u2019ll ensure to keep everything concise and present my answer clearly!",
                "format": "openai-responses-v1",
                "index": 0
              },
              {
                "type": "reasoning.encrypted",
                "data": "gAAAAABpCSlZCMlveuljLSDOwOKLZ0SEFLImTbnmu_30ouM3xCdfh5C-FyJwdX_EKu2ALiw1K3v6f-rELBBWIdMaM45jbQcgpsOAk8WsDipHwMqvcQ8RAIYkOtOiM5ZUtWZPtUOPBqr7j_RpMBy9qaiVFtUNwBTmOrw89kcCabp38zcGjcxr1cvVUtYsX-nBtvkXPf4Z789wSlOrDi2ybGJWam3kdAFhiBwRdYNzC9pn4Fs3PbE2hjU1hAfZbkNHGNJTftC95W4sTM-8MUPzypXcQONm03ZeOe5sLMk15hTNrwVUJ4ZTJI8B5v1kmaand6qPQdteD0WTKpex_eRdUey9dGXvVY7onsFyFG_BAFXk4tjcpqnl2bxqaqa7lqpg9fkXlBEPDbpev1TMRMJnda_v2o3IdzWlM3PP4KRdQaIZBoLWObJHCEUll44hEM8gjxmazqN-xNJa98GfhRXewckRMmMO-ap4ZA17qAfQZA6AR7n7d3hxF_-MNPe3iNnVg2dEGF-1AddZIhsXMZuD5PKVjYgg0Ms-GwC27l0fpqjnD71WdiNR0PR-8Bymh6nLKRhY1pM5FXmkTVSaBwFcxYO76XWJ8uxCnWobl9T43t--lCtNSBUJ-imzjUIuGRcPF6S_hlcnthOLP6iV2CvRISVxgtHwctx1-lXuN5ydfROS1ZI6Oni3wXYMonGk27NyyiUWLERrwe5RAPTGQoTSoeZnbGDnlWwsGdXb0uLiZBO43JFsXsbR7lDHfuiJHyl61L2UWLxSt6_jQjIAHQURD7gU389_9kl1LyRMjFz4CaEcTlxB2HxijOMp2IqBm4mRBaB5TAPriQSJ3e7werwqC-kAiNTkLj94tn1u31IaADRg8m9j9GrcI6mrUrirLrGX3HtzZu1OruOUzy_TJ7OFpP0GzLQ7Ab9NZjQhUB5lcgeT1Aol1anReCspN36SjQwclNIKZuNZfL_KzJixVulIOEhoK19fyyfgyaFQ7dC_4ngnEot8fCHueRx7U27AnZywqZgqsfuTkv_fAoFEp5GtPdoeOvcnXWjQfF3BYtZ6HVmmXZwvYBxUdrL1HH3NCmypb6Nu135_zb0I4yzq_Dl1edb1FumpqFjyVl2iIR2m0kUWW6mePKiNIezfHuOtvSCfQAWoDeGHLtE5qoc5-AgYqPyXB8fXzJ5d6Rr_owOoC2ed7blJYmzmzsIJvk1YrayrBcTCOqfGxA5hr1Mtnm5NfEz7vsqzG9ob5ig2dzPTOSpZ4HF9jkUl1UyDyOyK78zTz129Tt5kv-G0bDaxDh9lkEOT3zH_PT3LRTHayDb2FGa18PPNCnlAM7Av3xA_RJ_tBfoxySFqfw2xwqo6jXzpo6pIqI2BEWGkCzUlKwLTH1aaMFJRSRDl2DH7EsYSyOJjPzthQCiQoP_In_YwMZmCbcWxSA-OfTZiaXjQaSlmkBCkPA0EzL5i6acf1wPWZxm5XYWIJjS0cyKOT197nEYGM-WvThWYKFA5YQPDCv6hCmyaouCNZtB6WE7oP85J7aQVSX5Z3R05tpEqDvDoOZRRt0mHRkhQCeJeE2z4aqE4TA8jb6tBQ5w2hjUWcAHwAEbUvRfFtiogHJzw2sOO9ob8z4fbRlb2YrFD8Ms3kCw_RJt1J6X3leweXoyN1qzjuCwBVgsduUAFk2KG9Tr507lu-qPPswXSWM2nPL92fnr5VQxiYx73k-22hNjt3emdytVK4y5g17uw4YjNrGfk0wumWf4CWCqy3QVRHMazVxPQCMe3UVH7zgV-G80BG-uSEF2uXImBTSJU5hcCygt4uCarkP1-4PIwc7sBM1DymxRy36thTWt60AgBh5Yi-ClOrzlYuDGP2fBvZHNmpDVwu88JpEyDbS4exHv8bMQW6Fa2VR1Zd9IMeUYEWvO5wRbr6SBz-e99O7DC4AwXtVJzaZdRD4CHbaRscHjwvAqo1w2PjIElxqmcG4byRSIt8YuEX4YF7kjKPaX8hF6IJkcqXSiwfyNDHcfzK-5nnk1GQn9PNPHIITfG2c37Un0b82nxXlDDpJn0S2EiNwogojIZVh0mnRJpM54QhXjP6hU4MNnJvo73IPbpYZ_Qh5wS9XSj5CZpEtMgFIMuoY7tSe5tpJbqMihDyTpV8bcFdW4KcEVJX-8caop3GFDun2LxHnVdQRJqYXN08NaW4ltBIF7bNg7HwWMdKMFFgelNnm6BcKjmkR6l-DOD0fWqKF9AfATZWiJgmDvis2B9ezGx7kHGFa3FK_Kt9idXEAu8Yg7azfUK_9HZJ9h2ekqpBOvT-Dhb5jkfodfG8-sHRuoLFBOyvptFDW02EpVFgY8sv8arOLUAcOhkTXaJij_DHnNQe96DG9wam_R__dC-mcJXcCKuHgd3_zAR8eSt9snemAsyaoSXfn3hZRSVdWAYwNR5TcNtuvnIBg5YFkxxmf1uvCM6Xmrv4hc0tMCGiIXwQNNyQc7UPCZ_kL_PzzkjI27_7dSNL9_6ZSqjq8ZQME7c0ehe0FpZT2ANZ3gld9M-AuK57ljQsKjnA-cBX6Q6t453IA7hrKRXkOztwDkwXhweAowH_9hjWGPkHbpyOkewELLPuvzWHFlUVZNbiXcphHu5Q7Tv58eY7kvQfSw7NdiLq1FBdiNXSR7WCYfKohC5VDgGYY1lWkrVFF-iHc75T4JvkBInDO8yP586T56uhRIOvuEo5zaheNehE8KomnjbsuXKLJSL5li1E-K9xlmXH_wYd_5Aa8XqquQvuAdCTrh7aJg2wD8pdjH4gFaDplw0saSiSocbGHzqA6dHemQKDOwDb2k-S9ecj1rHINRX2-5RmAHjts8BPL9Nc-wci2upB8VsD8ycKpXDzrR6oYWzG8nuAk_jbsHCioyqit0bRENxnDbkzdGkaBBWDnuaYNuRXgKglqxPNrnFCiAD7FhZkoGu2ZAirFK-xBc2X14lKplIBiwpgZi4EglawuxcHt3hDXLtNFeHic0Mes2MFVa7pnMiQfLVA-yfvAsxH3pXJXN611-rE4QtR6_UIymdW_BvbsIH8BeLKLfK7SZKmuYyd3vU0CsqDfkbdU60G8B5hOWOWlD7Fs-HPd07sARB7_ip0m3P118WOhPPrvy8JBCWG4oMTM_1muY_IFm0B4AnzxpXvGvuuMjFsD3M6oUPYVIBVf20vto5wQkKmUs2Y87uJMFh_CTWABm6WWJrlSz04pms9h3CazRL4S5YG-10_Gj6gp0270M0VPcKH6zEix_M5cPUwdNyiLSlhxs2moZbsBUoXi96rz8waeO4_IwN_mkWdd0NiCxj4xoQ_rrkxVhIK0zVJ6PNBPsHoTZPMxlit2a_EjWCwtTqiYNeN1KIqxBhI-l3XbN1xeB7q4p2ERUNBK4svRmWMjDQYHli-pRPVjtqWROOKp4ybndbtWIp33LuwHxC3iSnCum_iY9EV8t_MOsWwnzUVj0jkk_ce101NSH-vlY_mJ9YEGuzLYrXcqb9DVp9Qa2z8gGmYIOYmWUkbNg0pK_nOheuES9kSs0uaX1iDbwmImh5t5hwr5Ys3z087g-zYSXBVhBNGa_ebaVTved8U6D5V-nYuVzFQGsvttMT_ieKJZjXHESyh9e52nOlZUVa2arxbc-R85J8Nmwy1gF7GfAZGNeiDFJ2zG7HDh0uB0h5t7KOPkLUl5-NOc7KrfKYt4aEG9YqBD4XKehlXvBU8PHj2lpVUwYZh4CJxNZyOQAB3fz_WwElm5q2psBYIwl6ydkMsLH1ZBKPg4orwnvJHWTJxQN-k6XuKbaz5w5CSxJ7sGsqu0UL4kEyFwU1Sj27VT0ZRoZFuSUYLaiDWutWkbc_xdit6_XUm22TZ_sJbSk8dLsJNOk6TctixMNA8A_l9xWbFdaOXEK3ZPeYtIMzxgSBMncCEp51c568H3Fi9BTANZNruKgVvrVJr5lWeOE31Mp4_qHTP7SWuwLJWGtpMfuQLr67i9676608ueGvqH2hHwbj2g6omRKQBzQwJ8iGUyiySM7WF1LUDc731zfw-h0f_y64z4jkMXsmRTOsz92GuOg6ouZExQBKR8dLPY5p0pIsnpyhp3lykU6YP-Iwd0R8Gzn4uWjLlZJs9qvPe3KARvg7kBaXkpof_GO2XjMJR1ToW1eK6RjhGOwFh9z66DvdC-xtITXp3RJRJ-_ezzB-SUGi4LS8ZPKdXVpHHoLCiAh-MWjxpCuAlDpK_syaZd70MIA22tSNNfhyu9AQjDLZaLW9tZjasm5DUye9qt6xK7Jcjx1zLvXNeR6MyYp0kYwhVC56k7AuWJq_IrOnopJrbdjMvLPpMjzu3SOpahKhs1314JqpN_qNdD_mwi_3WgfbZdfYaSWaUJdZiX85SfOfCndV_WINR19RjX5Cu6GNc8EDtPK8nJY4u54AzUwWJj2bdJUTrMkrw_JEl7VQYA_bxrdApoKgtVx-3su235L-nasCsWKIC7-ke9FU8DuGhXFNXdcGHE-n0BYlEEKjZ3Q5zll00UGktRzGkKWWUxSq4NnjmENLPIyr3PZD2K61doZZsBFe471T96Ji1i8Kn18WNAKYiXH8v3grRnypjyP28VuZli1_qXStIRPbax7e9DQu6kZ5h-AKQexgpH7RyrFPNDZw9h1YhoysXdduujCXDsYmS-sGKy9ttrkCgY0_lmwSEjTXceIJmH7AoP52PFxkJRqrUk67o9acBSIBtE3nOPcqeW-ncCCrxNPXqkG5m2pl6N2qsGizofe4Wf9HBmMNGlRrabP_wzk2-UvWRzbl_Y_Yjo6t67GzSAYWREAI8JsEiCwsw5XOsFLUzxt24RFCx4la-7YboWahmTHC6uYv1_gUH58bB1xEMpu654XDDMOxIf1fkx5afY1DQF5Z16eehZAl0LV7EnSWa-teEueynsy6bPv0EMcLjzwXu8HuPLXBu4p22LK-WrNS5On3SyWiYOSUqgnFN3lbpOQVqpnOo92uW1kTUBxSYyEUTmSItqtmg67Gpn1J2lwX_upTazCimN6JoHELe-CPhbrfmi2BJl5roeEIkYDswaGglajtd94AZBRZpSVEGkoYwnDyk8EbCLJz96z5l4Cd9zKJu5ONbOEmR6HyUuQl0spda90lY5mg478ju3dp03Za3QAH2Ut7Yzpbz3cDeounD6uwx33Fy6WyWRpq7h3wMKWOiUQaSY-tep0jRbbvfOr1LDbUVLh1hqzMjTryeMsjD4n9IBe0bss8VQs1Hl_cCS6BqYd6h7yoScIUXANi0A2K3AJ4RJ_zhRMWqhZ1sg8v8bu8r2AOl_5qNGsnl7-Uu3aEae6u4XDVm6X4ieJtYaL0hHwQ3wQdIXy--asvOogRCuthkljnu4Z8x8oziH1YO-UZRPctrY1xDR_x1ZnL-dOI4JYdywVbuGfWeYvrkXVOtH1UCT97mtmvomx41UBkuAyaqnEfPc-hcWprC73ElvaJD-nnbhgwRVKn5gcpqzXGJ3Iaod9K8_Pr-K_bCbgTs0KO4HJeYHA1wUOxE7C1XAPxJIqz_6jICjd-2WOtEeN5Ns_j6P8R35_p1q_Tn4yEHm_0wSmsqoUeHahJwVl0EFvhn1A_l4RWP8j-YHCmqlNHimzuy0RjGa1SCe5f4Tsp-4BMQ8qNiHNMwNC8dJCnHEDh5ZPQ4toD9d18tMcTLEngPIEaTv77KfTIJLHXYMoofGxSJglFb11jq1vcBinkfShkRprWbyL9FQ2SLmuu58vwECcisw==",
                "id": "rs_085e342e466c0fe7016909294aeda88197a98630a16898f3b9",
                "format": "openai-responses-v1",
                "index": 0
              }
            ]
          },
          "native_finish_reason": "completed"
        }
      ],
      "created": 1762208073,
      "model": "openai/gpt-5-mini",
      "object": "chat.completion",
      "service_tier": null,
      "system_fingerprint": null,
      "usage": {
        "completion_tokens": 827,
        "prompt_tokens": 443,
        "total_tokens": 1270,
        "completion_tokens_details": {
          "accepted_prediction_tokens": null,
          "audio_tokens": null,
          "reasoning_tokens": 704,
          "rejected_prediction_tokens": null,
          "image_tokens": 0
        },
        "prompt_tokens_details": {
          "audio_tokens": 0,
          "cached_tokens": 0
        },
        "cost": 0.00176475,
        "is_byok": false,
        "cost_details": {
          "upstream_inference_cost": null,
          "upstream_inference_prompt_cost": 0.00011075,
          "upstream_inference_completions_cost": 0.001654
        }
      },
      "provider": "OpenAI"
    }
  },
  {
    "request": {
      "base_url": "https://openrouter.ai/api/v1",
      "model": "openai/gpt-5-mini",
      "messages": [
        {
          "role": "user",
          "content": "A patient who has recently gone into remission from lymphoma was previously on high doses of opioids and is now facing challenges in weaning off them. The patient wonders if buprenorphine-naloxone (Suboxone) could be part of their tapering plan. \n\nConsidering the patient's situation, review the following options then select the best statement(s):\nI. Maintain the patient on their current opioid regimen, focusing on gradually reducing dosage over time without introducing new medications to avoid potential side effects.\nII. Transition the patient to methadone, which is approved for both pain and opioid use disorder management; it offers a highly regulated dosage and reduces potential withdrawal complications.\nIII. Initiate a rapid opioid tapering strategy, augmented with non-opioid pain management interventions, emphasizing complete opioid cessation as the primary goal.\nIV. Arrange a multidisciplinary consultation, involving pain management and psychiatry, to assess the psychological and physical aspects and develop an integrated tapering approach.\nV. Prescribe buprenorphine-naloxone, as it is effective for managing opioid use disorder symptoms, including withdrawal and cravings, even though its primary indication is not for chronic pain.\n\nAnswer Choices:\nA. I, II\nB. I, III\nC. I\nD. II, V\nE. I, II, IV\nF. II, III\nG. IV, V\nH. II, IV, V\nI. V\nJ. II, III, IV\nK. I, II, III\nL. III, V\nM. I, IV\nN. II\nO. II, IV\nP. III, IV\nQ. IV\nR. III\nS. I, V\nT. I, III, IV\nU. I, IV, V"
        }
      ],
      "reasoning_effort": "medium",
      "response_format": {
        "type": "json_schema",
        "json_schema": {
          "name": "answer",
          "strict": true,
          "schema": {
            "type": "object",
            "properties": {
              "answer": {
                "type": "string"
              },
              "answer_letter": {
                "type": "string",
                "enum": [
                  "A",
                  "B",
                  "C",
                  "D",
                  "E",
                  "F",
                  "G",
                  "H",
                  "I",
                  "J",
                  "K",
                  "L",
                  "M",
                  "N",
                  "O",
                  "P",
                  "Q",
                  "R",
                  "S",
                  "T",
                  "U"
                ]
              }
            },
            "required": [
              "answer",
              "answer_letter"
            ],
            "additionalProperties": false
          }
        }
      },
      "usage": {
        "include": true
      }
    },
    "response": {
      "id": "gen-1762208073-R1ehSXavsAqB97NKXzx6",
      "choices": [
        {
          "finish_reason": "stop",
          "index": 0,
          "logprobs": null,
          "message": {
            "content": "{\"answer\":\"G. Arrange multidisciplinary consultation (pain management + psychiatry) and consider buprenorphine\u2011naloxone as part of the plan. Buprenorphine\u2011naloxone is effective for treating opioid use disorder (reduces withdrawal/craving) and can be incorporated into a supervised taper/transition, but initiation and dosing need specialist input to avoid precipitated withdrawal and to manage pain. A multidisciplinary approach is recommended. Rapid tapers and simply staying on the same regimen without specialist involvement are not preferable; methadone is an alternative in some circumstances but requires opioid treatment program oversight and has distinct risks.\",\"answer_letter\":\"G\"}",
            "refusal": null,
            "role": "assistant",
            "annotations": null,
            "audio": null,
            "function_call": null,
            "tool_calls": null,
            "reasoning": "**Evaluating methadone options**\n\nI'm considering methadone as an option, but it's not always the first choice for outpatient settings unless it's a specialized clinic. If the patient is really struggling, simply sticking to the current regimen without adding medications might not be beneficial. It feels like IV and V could be better choices in this situation. I need to confirm this approach before coming to a final decision.",
            "reasoning_details": [
              {
                "type": "reasoning.summary",
                "summary": "**Evaluating methadone options**\n\nI'm considering methadone as an option, but it's not always the first choice for outpatient settings unless it's a specialized clinic. If the patient is really struggling, simply sticking to the current regimen without adding medications might not be beneficial. It feels like IV and V could be better choices in this situation. I need to confirm this approach before coming to a final decision.",
                "format": "openai-responses-v1",
                "index": 0
              },
              {
                "type": "reasoning.encrypted",
                "data": "gAAAAABpCSlTQ6kPio0EsaZsTt__FVfHXz_y1CdO3Va4BXPQ71VugWXPSXJlsVqDvdOloamACvznrx9st4OFU17-ueh3GwBXxnTUHw_vsx3QQQek0GlZM9CvxH0c7CGHJhRbjL27ko4ajSe3uz6a2fxymI5gBZaagdFIFTemXZ5dBdmN2neQ5DDcuyeJDLeANi4vZHSU8mTZEuBg6X3_gRVvBHvIOpWkGXIoJBO6zyxq41FgHqYkHFCYfL0g0WGUNby3lfZFwJZWD9Ex6IoEcUHP7ntYyg5VF_5KlJN9i3THGbH4Qol_NzPNpnvc5S1h1ZHEwqgGEQBvLmdh9znKOxb5jCR1R3-5J_B2N1IltBXl55Svg-CpY4QG0YEiOhrjvT94Wy0M7XBFR0lWd8PgJfE6W1TIJ-1sJV4AaCq8QsL4VW_SWYZrpBOKnNvtXeIrBFe4vKBNVqNu7hG4zCC2Yu82K3an694SwlnhoXr5wRWkDxKddOsu5JNoVPVQf0FHSfJXDKN44kWzEnv1MRBKcrTaD_iY-IWDCuAhbJq2oYdj4mcUQzSYiXTXWatS3xgHmWU5lhO0XPf-n1HLJn2L9Dtc6GXGuKRip9LgAbL7EhCgS-63Dpt2VwwhGDhVOe6mLJA3360maWH7cLIk5uvEA_tH4e1NaPSh_RxydvqPwSDSoFFGlHVpqdx8Dq4X-gNayRjSqp5qCg_WQXagx9VmPPOAFdE0cNRKaDUu2chgOeu0TriUProiWncS0KT-IcwrnkDjal0CYAy9VfKTJPpOZ_VXoiWaxZXHpdEYWZ0fofDJjW3iNmYQxxbb49NbqNcpmnkEhsipuWE9xnKGX62ygewLBmfbfyakK6DACxaJH_CE08cXbusp_X0Ly2OWfe3cTkYSxh3EiNy9Mqo0oKJlf3r72Jg00BgCY61U63gCCRfYxdFc0rNvdyIxCcRn_IQ-zqqbLBM5x-Lr3LJipFexopaoswdVAo6rH7HuIrk3JFkpSYvfYIz9ME9r644OG1QWVzzkNWzqqKCh7K-qK6bunTj8V2oVYS-4l2DN7OBn-7k5gCGSoq5FRpJNmMK1mTkBXWN0A7SygiT1EplYk-5wNJMPs1p9ElkUYVQLWvE-14AvR3q-l18Wp0pWiF0Cj8ht9Vxc9wBhjeKFOGNM4PGAiGBF_D9_pVyyuGuH_wtgv6hPho6uUfAbpRuTJgqCgB7fT6kVdw8nTiqAbF78UQg5giCGjfxcUcpm70SeLexGpBjWXVz308LPlWyLCvD1qz3ENWqqu2Qio0yLozDMkel0CVRHAj3iMw2TeSFmofWRmBheQt1FhRT_OLCV1tWJPHjI21ywsKSDLqaZwWaug2TNhtZ8OA6gfC2wIT1VrL70J18G0yv4KzbZAFbMN2alQJzRPdPiqVeSCCuxo6pjqjyUXNg4Fv8fb13Eppcb67NQiwl5kCpvSjFQB11HOr1gl4poSma4a_iX-QlPMrYue2SXMjMnQ2Qw9M6DvybnCLpM26_3s-J6sn5YfnHsYldAXKePy31F11YdjlgRFK9wouLOMAebC88q4iQt_kEPFTDSQxxWB9ekGYxi92ygbThGEaOH5AeQzG3oYP_nNlKanAu5llL_wa8Bwv7MH2RWeXqR0IwrOkjArxtXRuaItTe6GF3Vc1yJ4k9L8A-_QlfsePNbKI1Sg_CadvXPKEKXCFZAFkcmM6BFGJvx5ZgeBS82aCZtYoTa9b-QasxWa_4p4nA7KoiDmJzM-_HT-Ob8TxvQ67zd0YUnc1rHIhnBq19OQf94HBfFjLfUkg0YvMAfm6ZaQta0E8Q_SVE4aUWhIj9ePOeNfPRLQv5kDPvwcyDc-HH3SdZht5nJcV6Es7JtGBQ_SxH7KAKInRHqgoWemyht9k2_0Ge6QFw8pqwffoOkYrbP1FioFgaXO6baKJGQJF1RzDjpzxQ3hzA1-X-6YtWS61DI88UicnMmx8OmLkBJpAtp4S5VQhLVnZ80RhhuQfHynkwbc70_Kzh4RO1Vk3HH-QYxBB5liOU-_ZFj1jSmRFrLNVe8J7CqrxW0YEFKo0Oka_GJU0hWUd7k3ufSyK-WtTf2fcGJIDO8sXRt4oiShTbtswr2-2GcDNhld1LQzUPWM1WInCAlneB5fhB1nbpNpuiL27MxaN3Tb7857Ykg7f-OZHPBFXH0kAQN41tFCpyD5kGk1nUJXrEMoZkkP703_ykAw6uuDTUkpXUedVOUwbzohPHb_wfB62s0nK8kzGScrpW2srCZvzwiL1JCZyQM4IuxNaZN3lKSrnUjSav71casfYg1FaL0ZaMWarYrHmjGkmJbgt5TCkgDStU2-mK6IfuQFjVg7XyGJ0b_hWW9qyt0uXcIBwOBTJ4DPshokxLiKHRjfeYpcjCYCrIBowhn99ABpU9SPwAU4fJRv_tbN5rn5rWn-6OD0wPOEPawDEk13TQRtbDxx8awUQheC9CTpkDCRb65-UwKYf_Wc0qiHrwrE4JeP1Cv2Mne60-VAV3U4RoVWm3F56T6y7RdL3HyPFDWqeZclNBWagvW95Uc9M6gwJ2122sqwldt1XdlBOSY6zRekplE2UZm9bT9LdeD3G9J80IU1PJlOYxORgRxot11N4EAHyjQVc4eIUJPbCnLQCH_QtFNc5T4qlt4tm0r7Nm2g9FchOnwu-iWlWy9eSCtzlwzOYqaF4vHUam8GI8fZ2vnEyatl9-PrUi8xAhXrFzHyF26ZL710gc_o5nXsnVjNVzmQWhGVbDvJs3NWIbXDb04gE7uu-nnnfAF97Hp31I_KNH3MnoVNYN0_tO2h4avgEQ6InWjpoEHq_BIXHkZWZfwTD9RdQJi-zcxzc5jOqPY4lDZeq58PD3MN0UzWmSFJf9nD22_04lOOQZSmYtWUAC969T9BVlWZBT_uYb9yJtszftB7S-wcNQ-U-PASSxMVxFJxAACWIFzeKaq8QUcqJdKn_tAmb1IwdJ2Zymx-cPAVkRqQUmF0dLoYEP8NeXf_Ba-ZYtxULrQm9hOgQBEtqAsJlEoVQCDKRizlB3JYAj0F6YIgUqTFwKmaY_Jlvzk0kqRSBI8P4CMEgb6GjehrVJ2mc7pdB8uoDjhc6ZBtNloWZ3z-iXqYEltFkpwXbejPkS8NZIw5e5fju3ReKpvy1Uk-TdIzmhf9TAgcx2O1IDAc7Ef6vmF1prAWah9FB2Hm_BCW9TxUgEwU7qnk54Ds4F1YNoAm94Ger3-r-dfp5ta7dxygcLFP9juzzYaB9NaxxgXwZfoIqFhqiCzRqbZwj4OiWoXi2HB_l73zmiOI-Z1Q776hAn2DKuIqHlYjeGe1elko_DOlfRfE3WPWIwZOTI795LKjcfNNiaD4CI0A8Ga8yRAlULsQVH_z5EPwMU33MRBwob87rsSbkfGeXQuU_vbjbk2NKCd7zKOko20rPFOC1j8rsdo1VjXOxFBAlW6fPTeRfg7FKxVsu48_e_s0D8v9c3piPvAmCzE20aYvNGya7FMAOT2k9yBUFspkeMqiOEalOW_EndzslCmdshBgPhh79PMfyWEZ4WrrDZ99i-p_2ECxI4v8ThHa9FE4WhY31I4SmeEG1sCNwid85nT7vsXXugOKS6wknm-lcxK6OGE9wElYV1uol2xOA4HUiMem9qQ2MtFbD_hItwkcW9nPKr1l28sqIbEsiNY0DiinyeAYwIS4oFn2IMJmtGLPkiALNoj43vzkEWI0EZ7lo-H9GFvk3PkNxgQ1zR-G2-V1bw3S4wog116JEQcvfImmFUB-uu_6F8vWzM26XoImhfdgZFn_kcouE-q3B4mRdGSfDPRfx3jCONkKuuDsuGmgVODAjsinOY2YxVNT9-JdxTMeSuJncYbCD9YbvMHiGWzyW53f8pZX39q2r5Ovx4GJxpmKZspunARtH5r199xxLUF_PkyEyMFjkwp9J0bg0zmz3ba_PhGgm7jM2wPF8xODJ2ynpI6wH4B2ihBXLILR_lxYg8SausoK_1QzWFx-nLS85Ldtm5bp-U7bUZvCn-yS_1D6hLYQ8eKllnDRZC5T1sqJerW05uMJ9_O2YtfSKYLypsOAOEgRi16usc6-VIRfkmVhm-dbW39ABONUP0YDi4Eq8FmP3VbsU8FOKheKy2D35hhngquRBKJoLJ1EoNjUG_2WPnitMpELx530BIacngc0E_uMjufNaRvp0IZya6emkBNqYt0_ypHFTIhd2eHzolOr8Titol1OE-9XxYhMzfVTgYS5kSpsZruwxJ5Egx3dwGIwHS7nDRg6wRUKcNpsgkI_RY6PD5_Nex8NIZG1jutSVQeS7yT5mguWWYZhnojPsj8oYnJgO-4YNceJXiEG-jSmKN3iH83nPZK1mleS5HrclajFTQ0NK_u7_CdDnfpiHqG8Zw49VsXqJJJAY28fjIjykmEBF4piRHB3oYKJDFaR2QUW2E0vHhhigLi51LpVmIdCj_PLvwr4yly5GaHjUT0-VwF4CRYlfofi4Z_7xWLCkP6VPLx63Al3Eb7LxZYveQTswt10TxXrwY92qPuOQGpgGe6vioNWx5x6we221ujw_W05ZdhIgtZ8Imu87fGiskr2lyBJe3zYhck9nSruLULpTjwpvh0gIFlgFN-Yfmb3_2KX-HFwz9FpinV2bknWK3y4MohjGwntLyM9c0bYRBCcagu0GL2wl7nfDpudkx0-zT18ImwqM7uTsKXJ92gCm-izMOwLww8-WCGUfSt1CZe4aZk0-KBVMfzpxiFDyyAhj_xJEkJy9xLGU967JiYDrgo_Ufl-uwasRNXHh6EpWQcgGNoE4e2UQkH-f9956jra9pljzb5mulQVV8SF-qq00_lOZX8dzMFDJlnnONgULydghTZYZh-grC4xkhOGvqoB36KX8E5KZ5cWZIa-WkzUcyFBHrE9zO8P5NeOD6RnRdTWPxHFGKsTFfSYtPSDCs9L5mbFUWjY3H02GRUDcHwHllojsoNNuFkc87rAQO4KitEfEsIMES2AdLj18qYFYn_7AColvzuR519ZfOFo-glhOSvCXhL_Crz9stVA8qYZTMgUteDboNx_6KRU7m2AY9xjnimZ7mH5ASSL984I_pLE0fBJ1kvZmm5bGiEqnjL40H6iTwalR7g77YsdyHfwCToNig7g6ko_6NWZw==",
                "id": "rs_0afc0b3c46483805016909294a833c8190b0b0fa09b4112b2b",
                "format": "openai-responses-v1",
                "index": 0
              }
            ]
          },
          "native_finish_reason": "completed"
        }
      ],
      "created": 1762208073,
      "model": "openai/gpt-5-mini",
      "object": "chat.completion",
      "service_tier": null,
      "system_fingerprint": null,
      "usage": {
        "completion_tokens": 714,
        "prompt_tokens": 443,
        "total_tokens": 1157,
        "completion_tokens_details": {
          "accepted_prediction_tokens": null,
          "audio_tokens": null,
          "reasoning_tokens": 576,
          "rejected_prediction_tokens": null,
          "image_tokens": 0
        },
        "prompt_tokens_details": {
          "audio_tokens": 0,
          "cached_tokens": 0
        },
        "cost": 0.00153875,
        "is_byok": false,
        "cost_details": {
          "upstream_inference_cost": null,
          "upstream_inference_prompt_cost": 0.00011075,
          "upstream_inference_completions_cost": 0.001428
        }
      },
      "provider": "OpenAI"
    }
  }
]